MRNA is trading at $34.98 (+3.4%) amid continued positive momentum following its standalone flu vaccine filing and optimism around oncology data.
- Recent updates at the J.P. Morgan Healthcare Conference reiterated up to 10% revenue growth in 2026.
- 2025 forecasts were raised to $1.9B, exceeding estimates, supported by a strong $8.1B cash position.
- The stock has seen a significant 12% rise in the first week of 2026, aligning with broader biotech recovery.